Atara Biotherapeutics (ATRA) Non-Current Assets (2013 - 2026)

Atara Biotherapeutics' Non-Current Assets history runs 14 years deep, the most recent figure standing at $7.8 million for Q1 2026.

• Quarterly Non-Current Assets fell 77.55% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.7 million (down 78.51% YoY) and the FY2025 annual result came in at $8.0 million, down 81.85% from the prior year.
• Non-Current Assets was $7.8 million for Q1 2026 at Atara Biotherapeutics, down from $8.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $89.1 million in Q2 2022 and bottomed at $7.8 million in Q1 2026.
• A 5-year average of $53.4 million and a median of $58.8 million in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets jumped 38.27% — and 2025, when it slumped 81.85%.
• Atara Biotherapeutics' Non-Current Assets stood at $81.3 million in 2022, then retreated by 21.77% to $63.6 million in 2023, then sank by 30.54% to $44.2 million in 2024, then slumped by 81.85% to $8.0 million in 2025, then slipped by 2.48% to $7.8 million in 2026.
• Business Quant data shows ATRA's Non-Current Assets at $7.8 million in Q1 2026, $8.0 million in Q4 2025, and $11.7 million in Q3 2025.